Author: James L. Clark
Publisher:
ISBN:
Category : Breast
Languages : en
Pages : 126
Book Description
The Effects of Hormones and Drugs on the Growth of Carcinogen-induced Mammary Tumors
Author: James L. Clark
Publisher:
ISBN:
Category : Breast
Languages : en
Pages : 126
Book Description
Publisher:
ISBN:
Category : Breast
Languages : en
Pages : 126
Book Description
Comparative Oncology
Author: Alecsandru Ioan Baba
Publisher:
ISBN: 9789732714577
Category : Electronic books
Languages : en
Pages : 787
Book Description
Publisher:
ISBN: 9789732714577
Category : Electronic books
Languages : en
Pages : 787
Book Description
The Pineal Gland and Cancer
Author: C. Bartsch
Publisher: Springer Science & Business Media
ISBN: 364259512X
Category : Medical
Languages : en
Pages : 979
Book Description
The link between the pineal gland and cancer is a rapidly emerging research field due to promising experimental and clinical trials with melatonin. The pineal gland acts as a transducer of environmental light to regulate rhythmic processes, including reproductive function in seasonally breeding animals and the entrainment of circadian rhythms, such as the sleep-wake cycle, in man. This book elucidates the physiological significance of the pineal gland and surveys phenomena and mechanisms of pineal - tumor interaction at the neuroendocrine, neuroimmune, neural, and molecular levels. Yet unidentified low-molecular-weight pineal substances with tumor-inhibiting capacity, a possible involvement of melatonin in electromagnetic field effects on cancer, and the oncotherapeutic potential of melatonin are also addressed. The encouraging results should incite further research to elucidate the exact nature of the link between the pineal gland and cancer for the benefit of patients.
Publisher: Springer Science & Business Media
ISBN: 364259512X
Category : Medical
Languages : en
Pages : 979
Book Description
The link between the pineal gland and cancer is a rapidly emerging research field due to promising experimental and clinical trials with melatonin. The pineal gland acts as a transducer of environmental light to regulate rhythmic processes, including reproductive function in seasonally breeding animals and the entrainment of circadian rhythms, such as the sleep-wake cycle, in man. This book elucidates the physiological significance of the pineal gland and surveys phenomena and mechanisms of pineal - tumor interaction at the neuroendocrine, neuroimmune, neural, and molecular levels. Yet unidentified low-molecular-weight pineal substances with tumor-inhibiting capacity, a possible involvement of melatonin in electromagnetic field effects on cancer, and the oncotherapeutic potential of melatonin are also addressed. The encouraging results should incite further research to elucidate the exact nature of the link between the pineal gland and cancer for the benefit of patients.
The Heterogeneity of Cancer Metabolism
Author: Anne Le
Publisher: Springer
ISBN: 331977736X
Category : Medical
Languages : en
Pages : 186
Book Description
Genetic alterations in cancer, in addition to being the fundamental drivers of tumorigenesis, can give rise to a variety of metabolic adaptations that allow cancer cells to survive and proliferate in diverse tumor microenvironments. This metabolic flexibility is different from normal cellular metabolic processes and leads to heterogeneity in cancer metabolism within the same cancer type or even within the same tumor. In this book, we delve into the complexity and diversity of cancer metabolism, and highlight how understanding the heterogeneity of cancer metabolism is fundamental to the development of effective metabolism-based therapeutic strategies. Deciphering how cancer cells utilize various nutrient resources will enable clinicians and researchers to pair specific chemotherapeutic agents with patients who are most likely to respond with positive outcomes, allowing for more cost-effective and personalized cancer therapeutic strategies.
Publisher: Springer
ISBN: 331977736X
Category : Medical
Languages : en
Pages : 186
Book Description
Genetic alterations in cancer, in addition to being the fundamental drivers of tumorigenesis, can give rise to a variety of metabolic adaptations that allow cancer cells to survive and proliferate in diverse tumor microenvironments. This metabolic flexibility is different from normal cellular metabolic processes and leads to heterogeneity in cancer metabolism within the same cancer type or even within the same tumor. In this book, we delve into the complexity and diversity of cancer metabolism, and highlight how understanding the heterogeneity of cancer metabolism is fundamental to the development of effective metabolism-based therapeutic strategies. Deciphering how cancer cells utilize various nutrient resources will enable clinicians and researchers to pair specific chemotherapeutic agents with patients who are most likely to respond with positive outcomes, allowing for more cost-effective and personalized cancer therapeutic strategies.
Mechanisms of Carcinogenesis
Author: Elizabeth K. Weisburger
Publisher: Springer Science & Business Media
ISBN: 9400925263
Category : Medical
Languages : en
Pages : 210
Book Description
but also the possibility of intervention in specific stages. In Human behavior, including stress and other factors, plays an important role in neoplasia, although too little is known addition, variables which affect cancer development as well on the reasons for such development. Carcinogens, which as some endogenous factors can be better delineated help initiate the neoplastic process, may be either synthetic through such investigations. The topics of this volume encompass premalignant non or naturally-occurring. Cancer causation may be ascribed to invasive lesions, species-specific aspects of carcinogenicity, certain chemicals, physical agents, radioactive materials, viruses, parasites, the genetic make-up of the organism, and radiation, viruses, a quantum theory of carinogenesis, onco bacteria. Humans, eumetazoan animals and vascular plants genes, and selected environmental carcinogens. are susceptible to the first six groups of cancer causes, whe reas the last group, bacteria, seems to affect only vascular plants. Neoplastic development may begin with impairment ofJmdy defenses by a toxic material (carcinogen) which acts as an initiator, followed by promotion and progression to an overt neoplastic state. Investigation of these processes Series Editor Volume Editor allows not only a better insight into the mechanism of action Hans E. Kaiser Elizabeth K. Weisburger vii ACKNOWLEDGEMENT Inspiration and encouragement for this wide ranging project on cancer distribution and dissemination from a comparative biological and clinical point of view, was given by my late friend E. H. Krokowski.
Publisher: Springer Science & Business Media
ISBN: 9400925263
Category : Medical
Languages : en
Pages : 210
Book Description
but also the possibility of intervention in specific stages. In Human behavior, including stress and other factors, plays an important role in neoplasia, although too little is known addition, variables which affect cancer development as well on the reasons for such development. Carcinogens, which as some endogenous factors can be better delineated help initiate the neoplastic process, may be either synthetic through such investigations. The topics of this volume encompass premalignant non or naturally-occurring. Cancer causation may be ascribed to invasive lesions, species-specific aspects of carcinogenicity, certain chemicals, physical agents, radioactive materials, viruses, parasites, the genetic make-up of the organism, and radiation, viruses, a quantum theory of carinogenesis, onco bacteria. Humans, eumetazoan animals and vascular plants genes, and selected environmental carcinogens. are susceptible to the first six groups of cancer causes, whe reas the last group, bacteria, seems to affect only vascular plants. Neoplastic development may begin with impairment ofJmdy defenses by a toxic material (carcinogen) which acts as an initiator, followed by promotion and progression to an overt neoplastic state. Investigation of these processes Series Editor Volume Editor allows not only a better insight into the mechanism of action Hans E. Kaiser Elizabeth K. Weisburger vii ACKNOWLEDGEMENT Inspiration and encouragement for this wide ranging project on cancer distribution and dissemination from a comparative biological and clinical point of view, was given by my late friend E. H. Krokowski.
Withrow and MacEwen's Small Animal Clinical Oncology
Author: Stephen J. Withrow
Publisher: Elsevier Health Sciences
ISBN: 1437723624
Category : Medical
Languages : en
Pages : 775
Book Description
With a unique focus on the most effective interventional techniques, Withrow & MacEwen's Small Animal Clinical Oncology, 5th Edition tells the full story of cancer in dogs and cats - what it is, how to diagnose it, and how to treat many of the most common cancers encountered in clinical practice. Nearly 500 color photographs, diagrams, x-rays, and gross views depict the clinical manifestations of various cancers. This edition covers the latest advances in clinical oncology, including chemotherapy, surgical oncology, and diagnostic techniques. With contributions from 65 veterinary oncology experts, this authoritative reference is a must-have for current, evidence-based therapeutic strategies on canine and feline oncology. "I really love this book. If you are interested in veterinary oncology, have a flick through this book online or at a conference when you get the chance. I hope that you agree with me that this is the definitive oncology reference source for the early 21st century and that you feel compelled to buy it. Your patients will thank you for it." Reviewed by: Gerry Polton MA VetMB MSc(Clin Onc) DipECVIM-CA(Onc) MRCVS, UK Date: July 2014 Cutting-edge information on the complications of cancer, pain management, and the latest treatment modalities prepares you to diagnose and treat pets with cancer rather than refer cases to a specialist. A consistent format for chapters on body system tumors includes coverage of incidence and risk factors, pathology, natural behavior of tumors, history and clinical signs, diagnostic techniques and workup, treatment options, and prognosis for specific malignancies. A systems approach to the diagnosis and management of cancer facilitates access to information about the many malignancies affecting small animal patients. Nearly 500 color images provide accurate depictions of specific diseases and procedures. Helpful drug formularies provide quick access to information on indications, toxicities, and recommended dosages for chemotherapeutic and analgesic drugs used in cancer treatment. Expert contributors provide in-depth coverage of the most current information in his or her respective specialty in veterinary oncology. Chemotherapy protocols are included when case studies prove clinical efficacy. Discussion of compassion and supportive care for the management of pain, nutritional needs, and grief includes methods for handling the pet's pain and nutritional complications as well as the pet owner's grief when treatment is not successful. Thoroughly UPDATED chapters cover the most recent changes in the clinical management of melanoma, mast cell tumors, tumors of the skeletal system, tumors of the endocrine system, tumors of the mammary gland, urinary cancers, nervous system cancers, lymphoma, and histiocytic diseases. NEW Clinical Trials and Developmental Therapeutics chapter discusses the various phases of clinical trials as well as current challenges and opportunities in oncology drug development. NEW! A focus on the best recommended treatment options highlights therapeutic strategies that have been vetted by veterinary oncology experts. NEW co-author Dr. Rodney L. Page adds his valuable perspective, expertise, and research experience.
Publisher: Elsevier Health Sciences
ISBN: 1437723624
Category : Medical
Languages : en
Pages : 775
Book Description
With a unique focus on the most effective interventional techniques, Withrow & MacEwen's Small Animal Clinical Oncology, 5th Edition tells the full story of cancer in dogs and cats - what it is, how to diagnose it, and how to treat many of the most common cancers encountered in clinical practice. Nearly 500 color photographs, diagrams, x-rays, and gross views depict the clinical manifestations of various cancers. This edition covers the latest advances in clinical oncology, including chemotherapy, surgical oncology, and diagnostic techniques. With contributions from 65 veterinary oncology experts, this authoritative reference is a must-have for current, evidence-based therapeutic strategies on canine and feline oncology. "I really love this book. If you are interested in veterinary oncology, have a flick through this book online or at a conference when you get the chance. I hope that you agree with me that this is the definitive oncology reference source for the early 21st century and that you feel compelled to buy it. Your patients will thank you for it." Reviewed by: Gerry Polton MA VetMB MSc(Clin Onc) DipECVIM-CA(Onc) MRCVS, UK Date: July 2014 Cutting-edge information on the complications of cancer, pain management, and the latest treatment modalities prepares you to diagnose and treat pets with cancer rather than refer cases to a specialist. A consistent format for chapters on body system tumors includes coverage of incidence and risk factors, pathology, natural behavior of tumors, history and clinical signs, diagnostic techniques and workup, treatment options, and prognosis for specific malignancies. A systems approach to the diagnosis and management of cancer facilitates access to information about the many malignancies affecting small animal patients. Nearly 500 color images provide accurate depictions of specific diseases and procedures. Helpful drug formularies provide quick access to information on indications, toxicities, and recommended dosages for chemotherapeutic and analgesic drugs used in cancer treatment. Expert contributors provide in-depth coverage of the most current information in his or her respective specialty in veterinary oncology. Chemotherapy protocols are included when case studies prove clinical efficacy. Discussion of compassion and supportive care for the management of pain, nutritional needs, and grief includes methods for handling the pet's pain and nutritional complications as well as the pet owner's grief when treatment is not successful. Thoroughly UPDATED chapters cover the most recent changes in the clinical management of melanoma, mast cell tumors, tumors of the skeletal system, tumors of the endocrine system, tumors of the mammary gland, urinary cancers, nervous system cancers, lymphoma, and histiocytic diseases. NEW Clinical Trials and Developmental Therapeutics chapter discusses the various phases of clinical trials as well as current challenges and opportunities in oncology drug development. NEW! A focus on the best recommended treatment options highlights therapeutic strategies that have been vetted by veterinary oncology experts. NEW co-author Dr. Rodney L. Page adds his valuable perspective, expertise, and research experience.
Research Awards Index
Author:
Publisher:
ISBN:
Category : Medicine
Languages : en
Pages : 1212
Book Description
Publisher:
ISBN:
Category : Medicine
Languages : en
Pages : 1212
Book Description
Journal of the National Cancer Institute
Author:
Publisher:
ISBN:
Category : Cancer
Languages : en
Pages : 1108
Book Description
"Summaries of papers" contained in the journal accompany each issue, 19--
Publisher:
ISBN:
Category : Cancer
Languages : en
Pages : 1108
Book Description
"Summaries of papers" contained in the journal accompany each issue, 19--
Oral Contraceptives and Breast Cancer
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309044936
Category : Medical
Languages : en
Pages : 196
Book Description
At least 10.7 million American women use oral contraceptives (OCs). The potential connection with breast cancer has caused concern among these OC users and uncertainty among many of their physicians. This new volume offers the most up-to-date information available on this critical topic. While the best available knowledge does not support any fundamental change in clinical practice with respect to the use of OCs, this book offers specific recommendations for more research to fully resolve the relationship between OCs and breast cancer. Noting consumer confusion, the volume includes a concise summary of benefits, risks, and other practical information for contraceptive users and their doctors. The volume presents current data on changes in patterns of OC use, differences in risk at different ages, the benefits of OCs, and more. Oral Contraceptives and Breast Cancer will be important reading for obstetricians/gynecologists and other health professionals, their patients who use OCs, contraceptive manufacturers, women's health advocates, policymakers, and researchers.
Publisher: National Academies Press
ISBN: 0309044936
Category : Medical
Languages : en
Pages : 196
Book Description
At least 10.7 million American women use oral contraceptives (OCs). The potential connection with breast cancer has caused concern among these OC users and uncertainty among many of their physicians. This new volume offers the most up-to-date information available on this critical topic. While the best available knowledge does not support any fundamental change in clinical practice with respect to the use of OCs, this book offers specific recommendations for more research to fully resolve the relationship between OCs and breast cancer. Noting consumer confusion, the volume includes a concise summary of benefits, risks, and other practical information for contraceptive users and their doctors. The volume presents current data on changes in patterns of OC use, differences in risk at different ages, the benefits of OCs, and more. Oral Contraceptives and Breast Cancer will be important reading for obstetricians/gynecologists and other health professionals, their patients who use OCs, contraceptive manufacturers, women's health advocates, policymakers, and researchers.
Hormonal Contraception and Post-menopausal Hormonal Therapy
Author: IARC Working Group on the Evaluation of Carcinogenic Risks to Humans
Publisher: World Health Organization
ISBN:
Category : Medical
Languages : en
Pages : 692
Book Description
Evaluates evidence for an increased risk of cancer in women using combined oral contraceptives, progestogen-only hormonal contraceptives, post-menopausal estrogen therapy, and post-menopausal estrogen-progestogen therapy. Although the carcinogenicity of these preparations has been extensively investigated, the book stresses the many complex methodological issues that must be considered when interpreting findings and weighing results. Evidence of an association between use of these preparations and positive effects on health, including a reduced risk of some cancers, is also critically assessed. The first and most extensive monograph evaluates evidence of an association between the use of combined oral contraceptives and cancer at nine sites. Concerning breast cancer, the evaluation concludes that, even if the association is causal, the excess risk for breast cancer associated with patterns of use that are typical today is very small. Studies of predominantly high-dose preparations found an increased risk of hepatocellular carcinoma in the absence of hepatitis viruses. Citing these findings, the evaluation concludes that there is sufficient evidence in humans for the carcinogenicity of combined oral contraceptives. The evaluation also found sufficient evidence for the carcinogenicity of some, but not all, combined preparations in animals. Combined oral contraceptives were classified as carcinogenic to humans. The evaluation also cites conclusive evidence that these agents have a protective effect against cancers of the ovary and endometrium. Progestogen-only contraceptives are evaluated in the second monograph, which considers the association with cancer at six sites. The evaluation found no evidence of an increased risk for breast cancer. Although the evaluation found sufficient evidence in animals for the carcinogenicity of medroxyprogesterone acetate, evidence for the carcinogenicity of progestogen-only contraceptives in humans was judged inadequate. Progestogen-only contraceptives were classified as possibly carcinogenic to humans. The third monograph, on post-menopausal estrogen therapy, considers evidence of an association with cancer at eight sites. Findings from a large number of epidemiological studies indicate a small increase in the risk of breast cancer in women who have used these preparations for five years or more. Studies consistently show an association between use of post-menopausal estrogen therapy and an increased risk for endometrial cancer. Data on the association with other cancers were either inconclusive or suggested no effect on risk. The evaluation concludes that post-menopausal estrogen therapy is carcinogenic to humans. The final monograph evaluates the association between the use of post-menopausal estrogen-progestogen therapy and cancer at four sites. The evaluation of limited data on breast cancer found an increased relative risk observed with long-term use. Data were judged insufficient to assess the effects of past use and of different progestogen compounds, doses, and treatment schedules. For endometrial cancer, the evaluation found an increase in risk relative to non-users when the progestogen was added to the cycle for 10 days or fewer. Post-menopausal estrogen-progestogen therapy was classified as possibly carcinogenic to humans. Concerning post-menopausal therapy in general, the book notes that evidence of carcinogenic risks must be placed in perspective of potential benefits. The prevention of osteoporotic fractures is cited as the best-established benefit. Evidence also suggests that estrogen prevents heart disease and may prevent memory loss and dementia.
Publisher: World Health Organization
ISBN:
Category : Medical
Languages : en
Pages : 692
Book Description
Evaluates evidence for an increased risk of cancer in women using combined oral contraceptives, progestogen-only hormonal contraceptives, post-menopausal estrogen therapy, and post-menopausal estrogen-progestogen therapy. Although the carcinogenicity of these preparations has been extensively investigated, the book stresses the many complex methodological issues that must be considered when interpreting findings and weighing results. Evidence of an association between use of these preparations and positive effects on health, including a reduced risk of some cancers, is also critically assessed. The first and most extensive monograph evaluates evidence of an association between the use of combined oral contraceptives and cancer at nine sites. Concerning breast cancer, the evaluation concludes that, even if the association is causal, the excess risk for breast cancer associated with patterns of use that are typical today is very small. Studies of predominantly high-dose preparations found an increased risk of hepatocellular carcinoma in the absence of hepatitis viruses. Citing these findings, the evaluation concludes that there is sufficient evidence in humans for the carcinogenicity of combined oral contraceptives. The evaluation also found sufficient evidence for the carcinogenicity of some, but not all, combined preparations in animals. Combined oral contraceptives were classified as carcinogenic to humans. The evaluation also cites conclusive evidence that these agents have a protective effect against cancers of the ovary and endometrium. Progestogen-only contraceptives are evaluated in the second monograph, which considers the association with cancer at six sites. The evaluation found no evidence of an increased risk for breast cancer. Although the evaluation found sufficient evidence in animals for the carcinogenicity of medroxyprogesterone acetate, evidence for the carcinogenicity of progestogen-only contraceptives in humans was judged inadequate. Progestogen-only contraceptives were classified as possibly carcinogenic to humans. The third monograph, on post-menopausal estrogen therapy, considers evidence of an association with cancer at eight sites. Findings from a large number of epidemiological studies indicate a small increase in the risk of breast cancer in women who have used these preparations for five years or more. Studies consistently show an association between use of post-menopausal estrogen therapy and an increased risk for endometrial cancer. Data on the association with other cancers were either inconclusive or suggested no effect on risk. The evaluation concludes that post-menopausal estrogen therapy is carcinogenic to humans. The final monograph evaluates the association between the use of post-menopausal estrogen-progestogen therapy and cancer at four sites. The evaluation of limited data on breast cancer found an increased relative risk observed with long-term use. Data were judged insufficient to assess the effects of past use and of different progestogen compounds, doses, and treatment schedules. For endometrial cancer, the evaluation found an increase in risk relative to non-users when the progestogen was added to the cycle for 10 days or fewer. Post-menopausal estrogen-progestogen therapy was classified as possibly carcinogenic to humans. Concerning post-menopausal therapy in general, the book notes that evidence of carcinogenic risks must be placed in perspective of potential benefits. The prevention of osteoporotic fractures is cited as the best-established benefit. Evidence also suggests that estrogen prevents heart disease and may prevent memory loss and dementia.